Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Bioavailability & Absorption Objectives Factors affecting Bioavailability The calculation of Bioavailability (F) Absolute vs. Relative Bioavailability The effect of ka on [ ]-time profiles What happens if the dose does not begin to be absorbed immediately? What is the difference between an SR and an EC product? Bioavailability & Absorption 400 mg of moxifloxacin is administered orally to Mr BB, a 68 yr old male who weighs 75 kg. Blood samples were drawn following the dose and the plasma concentration determined. It is known that about 20% of a moxifloxacin dose is excreted in the urine unchanged. A further 20% is excreted unchanged in the bile and the rest is metabolised to either M1 (sulpho) or M2 (acyl-glucuronide) Time Plasma Conc Parameter Estimates (hr) (mg/L) ka = 2.365 hr-1 0.0 0.00 K = 0.06899 hr-1 0.25 0.88 0.5 1.40 T½ = 10.04 hr 1 1.86 AUCI =33.0 mg*hr/L 1.5 1.98 V/F = 175.69 when F=1 2 1.99 4 1.77 But does F=1 in this patient? 8 1.34 CPS says F = 0.9 …? 12 24 1.02 0.44 Definitions: Bioavailability: relative amount of an administered dose which reaches the general circulation and the rate at which this occurs. Relative to either and IV dose (Absolute bioavailability) or to another formulation of unknown F (Relative bioavailability). Definitions: Bioequivalence: The term applied to generic formulations of the same active ingredient and dose are said to be bioequivalent when the profiles of drug or metabolite(s) or both are similar. (considers both rate & extent) Definitions: Bioequivalence: Similar pharmacokinetic profiles of drug or metabolite(s) or both The degree of similarity between profiles is established statistically using Cmax and AUC as endpoints. Bioequivalence implies that with similar profiles, two bioequivalent drug products can be expected to have the same systemic effect (both therapeutic and adverse) Conducting a Bioavailability Study 1000 Test Reference Concentration (ng/mL) Test and Reference given in a minimum number of subjects (12) generally young males Controlled Conditions on separate occassions Assumption: Products shown to be bioequivalent in young males are assumed to be bioequivalent in the population that will use them, regardless of age, sex, and ethnic background. 100 10 1 0.1 0 2 4 6 Hours 8 10 12 Conducting a Bioavailability Study Test and Reference in a 2-way cross-over design in a minimum number of subjects (12) under controlled conditions Measure drug concentration with a specific and sensitive method Estimate AUC and CMAX Test Reference Concentration (ng/mL) Sample to capture CMAX and 80% of AUC (~4 half-lives 90% and generally > 80% in all) 1000 100 10 1 0.1 0 2 4 6 Hours 8 10 12 Parameters for Estimating Bioavailability Measures of Rate: Maximum concentration [Cmax], absorption rate constant [ka] Cmax Concentration (mg/L) 6.0 5.0 4.0 Tmax 2.0 1.0 0.0 0.0 2.0 4.0 Hours 6.0 Is Cmax a good measure of absorption rate? Answer: No ! …. Cmax is not a pure measure of rate … if we double the dose, Cmax will change (ka might not) But it is easy to estimate 7.0 3.0 Estimating Rate 8.0 10.0 and in a profile there is no argument about the highest measured concentration. Parameters for Estimating Bioavailability Estimating Extent Measures of Extent: Area Under the Curve [AUC] Is AUC a good measure of the extent of absorption? AUC 7.0 Concentration (mg/L) 6.0 5.0 Answer: Yes ! …. 4.0 3.0 2.0 1.0 0.0 0.0 2.0 4.0 Hours 6.0 8.0 10.0 Even based on trapezoidal rule AUC is a good measure of extent Calculating Bioavailability Mean Data based on 23 subjects Data from Yacobi, J Clin Pharmacol 2000; 40: 826-35 Test Reference 90 Concentration (ng/mL) Then calculate the Relative ratio of AUC Test / reference 80 Test 70 Reference 60 50 40 30 20 10 0 AUC0-∞ 27.0 ± 5.9 (ng x hr / mL) Relative Ratio: 26.3 ± 5.3 0 102.66 Questions: What does 27.0 ± 5.9 mean? What does 102.66 mean? 5 10 Hours 15 20 Factors Affecting Bioavailability Physiologic factors 1. 2. 3. 4. 5. 6. pH Stomach ~ 1 and intestine ~ 6 Surface area of the of the intestine – microvilli Presence of carrier proteins for absorption & exsorption (Pgp) Enzymes; endogenous and bacterial GI blood flow Gastric Emptying & intestinal transit (Pgp or MDR1) Physicochemical Properties of the Drug 1. 2. 3. 4. 5. pKa Water & lipid solubility Molecular size Stability in GI environment (pH) Specificity for carrier proteins and enzymes (Pgp or MDR1) Factors Affecting Bioavailability Physiologic factors 1. 2. 3. 4. 5. 6. Factors which change pH Stomach ~ 1 and intestine ~ 6 Surface area of the of the intestine microvilli the –environment. Presence of carrier proteins for absorption & exsorption (Pgp) Enzymes; endogenous and bacterial FOOD GI blood flow Affects pH, Gastric Emptying & intestinal transit (Pgp MDR1) Bloodorflow Gastric emptying Interactions enzymes Physicochemical Properties of thewith Drug 1. 2. 3. 4. 5. pKa Water & lipid solubility DRUGS Molecular size Affect Blood flow Stability in GI environment (pH) Gastric emptying Specificity for carrier proteinsInteractions and enzymeswith (Pgpenzymes or MDR1) Factors Affecting Bioavailability Food can affect both rate (ka) and extent (AUC) of absorption. No general statement of the effect of food can be made. Effect depends on the drug and the nature of the meal. Food can increase / decrease or have no effect on either rate (ka) or extent (AUC). Factors Affecting Bioavailability DRUGS, & Alternative Medicines can affect both rate (ka) & extent (AUC) of absorption No general statement of the effect of drugs can be made. Effect depends on the two drugs involved in the interaction and the mechanism of interaction…if known! inhibition of MDR1, change in pH, GI transit, blood flow… Calculating Bioavailability 400 mg of moxifloxacin is administered orally to Mr BB, a 68 yr old male who weighs 75 kg. Blood samples were drawn following the dose and the plasma concentration determined. It is known that about 20% of a moxifloxacin dose is excreted in the urine unchanged. A further 20% is excreted unchanged in the bile and the rest is metabolised to either M1 (sulpho) or M2 (acyl-glucuronide) Time Plasma Conc Parameter Estimates (hr) (mg/L) ka = 2.365 hr-1 0.0 0.00 K = 0.06899 hr-1 0.25 0.88 0.5 1.40 T½ = 10.04 hr 1 1.86 AUCI =33.0 mg*hr/L 1.5 1.98 V/F = 175.69 when F=1 2 1.99 4 1.77 But does F=1 in this patient? 8 1.34 CPS says F = 0.9 …? 12 24 1.02 0.44 Calculating Bioavailability To estimate absolute bioavailability in Mr BB, 400 mg of moxifloxacin is administered as an IV bolus. Blood samples were drawn following the dose and the plasma concentration determined. It is known that about 20% of a moxifloxacin dose is excreted in the urine unchanged. A further 20% is excreted unchanged in the bile and the rest is metabolised to either M1 (sulpho) or M2 (acyl-glucuronide) Time (hr) 0 2 6 12 24 36 48 Plasma Conc (mg/L) Questions to Solve 2.32 1.76 1.16 0.5 0.22 BLOQ 1. 2. 3. What model best describes profile? Calculate AUC, K, T½, V & Cl Calculate F for Mr BB Graph Patient Data Using semi-log paper, or Excel graph the data following IV bolus administration of 400 mg of moxifloxacin 10 6 3 Time (hr) 0 2 6 12 24 36 48 1 0.6 Concentration (mg/L) 10.0 0.4 0.2 1.0 0.1 0 0.1 0 4 4 8 8 12 10 16 20 Hours 24 28 14 18 32 36 22 24 Plasma Conc (mg/L) 2.32 1.76 1.16 0.5 0.22 BLOQ Graph Patient Data What model best describes this profile? Concentration (mg/L) 10.0 1.0 0.1 0 4 8 12 16 20 Hours 24 28 32 36 Terminal elimination phase is log-linear… 1 Compartment Model with first order elimination (K) Calculating Bioavailability To estimate absolute bioavailability in Mr BB, 400 mg of moxifloxacin is administered as an IV bolus. Blood samples were drawn following the dose and the plasma concentration determined. It is known that about 20% of a moxifloxacin dose is excreted in the urine unchanged. A further 20% is excreted unchanged in the bile and the rest is metabolised to either M1 (sulpho) or M2 (acyl-glucuronide) Time (hr) 0 2 6 12 24 36 48 Plasma Conc (mg/L) Questions to Solve 2.32 1.76 1.16 0.5 0.22 BLOQ 1. What model best describes profile? 2. Calculate AUC, K, T½, V & Cl 3. F for Mr YouCalculate should solve thisBB problem on your own. This will not be covered in Class. Use the associated Excel File to check your answers 1-Compartment IV Dosing AUC 38.38 mg*hr/L K 0.0694 hr-1 T½ 9.98 hr Cl 10.42L/hr Calculating Bioavailability To estimate absolute bioavailability in Mr BB, 400 mg of moxifloxacin is administered as an IV bolus. Blood samples were drawn following the dose and the plasma concentration determined. It is known that about 20% of a moxifloxacin dose is excreted in the urine unchanged. A further 20% is excreted unchanged in the bile and the rest is metabolised to either M1 (sulpho) or M2 (acyl-glucuronide) Time (hr) 0 2 6 12 24 36 48 Plasma Conc (mg/L) 2.32 1.76 1.16 0.5 0.22 BLOQ Parameter Estimates K = 0.0694 hr-1 T½ = 9.98 hr AUCI =38.38 mg*hr/L V = 150.12 L Calculating Bioavailability To estimate absolute bioavailability in Mr BB, 400 mg of moxifloxacin is administered as an IV bolus. Blood samples were drawn following the dose and the plasma concentration determined. It is known that about 20% of a moxifloxacin dose is excreted in the urine unchanged. A further 20% is excreted unchanged in the bile and the rest is metabolised to either M1 (sulpho) or M2 (acyl-glucuronide) Time (hr) 0 2 6 12 24 36 48 Plasma Conc Questions to Solve (mg/L) 2.32 1.76 1.16 0.5 0.22 BLOQ 1. 2. 3. What model best describes profile? Calculate AUC, K, T½, V & Cl Calculate F for Mr BB In order to calculate the absolute bioavailability for moxifloxacin in this patient we will need to give Mr. BB an IV dose (data on left) and compare it to the oral data. Calculating Bioavailability Why are we comparing AUC’s? What happens to AUC if we change the dose? If I give the same patient the same dose of a drug (400 mg) will the AUC always be the same? … if NOT when NOT? Change volume Change half-life Change clearance Calculating Bioavailability Concentration (mg/L) 2.5 Oral 2 IV 1.5 1 0.5 0 0 10 20 30 40 Hours AUCORAL = 33.000 mg*hr/L – from previous Slide Pak AUCIV = 38.386 mg*hr/L – Just calculated F=? Calculating Bioavailability Oral Data IV Data L F = AUCORAL / AUC IV = 33.00 / 38.39 = 85.97% F = 85.97% CPS: F = 90% Is it wrong? Bioavailability (F) & Other parameters IV Data Oral Data L Inspect other data: Should Clearance and Volume change as a result of a change in the route of administration? Clearance is calculated as Dose / AUC. Is the Dose really 400 mg if F is 85.97%? Bioavailability (F) & Other parameters IV Data Oral Data L Ratio of Clearance (Cl IV and ClORAL) Cl IV= 10.42 L/hr and ClORAL = 12.12 L/hr Ratio = 10.42 / 12.12 = 0.8597 (Same ratio as ratio of AUC (F)) How should Clearance following and oral dose be calculated? Bioavailability (F) & Other parameters IV Data Oral Data L Clearance following an Oral Dose (ClORAL) Cl ORAL= (F x Dose)/AUC = 0.8597 x 400 mg / 33.00 mg * hr/L = 10.421 L/hr Bioavailability (F) & Other parameters IV Data Oral Data L Clearance following an Oral Dose (ClORAL) Clearance is constant. It should not change when route changes. If clearance is calculated to be different than ClIV, it is because F is not known or F is different than expected. When F is not known, F is commonly assumed to be 1 (or left out of the equation) and then Clearance is best described as Apparent Oral Clearance. Bioavailability (F) & Other parameters IV Data Oral Data L Inspect other data: Should Volume change as a result of a change in the route of administration? Clearance is calculated from K x V and Dose / AUC. Is the Volume really 175.69 L if F is 85.97%? Bioavailability (F) & Other parameters IV Data Oral Data L Ratio of Volumes (V IV and VORAL) VIV= 150.12 L and VORAL = 175.69 L Ratio = 150.12 / 175.69 = 0.8597 (Same ratio as ratio of AUC (F) and ratio of clearances) How should Volume be calculated following and oral dose? Bioavailability (F) & Other parameters IV Data Oral Data L Volumes following an Oral Dose (V IV and VORAL) Since Cl = K x V and Cl = F x Dose / AUC then: K x V = F x Dose / AUC and VORAL = F x Dose / K x AUC = ((0.8597)(400)) / ((0.0694)(175.69)) = 150.159 L Bioavailability (F) & Other parameters IV Data Oral Data L Volume following an Oral Dose (VORAL) Volume should remain constant. It should not change when route changes. If the volume following and oral dose is different than the volume following an IV dose, it is because F is not known or F is different than expected. When F is not known, F is commonly assumed to be 1 and then Volume is best described as Apparent Oral Volume of Distribution. Bioavailability (F) & Other parameters IV Data Oral Data L Apparent Clearance (FDose/AUC) Volume (F= 85.97) L/hr L 10.42 150.1 Absorption Rate - ka Objectives Factors affecting Bioavailability The calculation of Bioavailability (F) Absolute vs. Relative Bioavailability The effect of ka on [ ]-time profiles What happens if the dose does not begin to be absorbed immediately? What is the difference between an SR and an EC product? Absorption Rate - ka 400 mg of moxifloxacin is administered orally to Mr BB, a 68 yr old male who weighs 75 kg. Blood samples were drawn following the dose and the plasma concentration determined. It is known that about 20% of a moxifloxacin dose is excreted in the urine unchanged. A further 20% is excreted unchanged in the bile and the rest is metabolised to either M1 (sulpho) or M2 (acyl-glucuronide) Time Plasma Conc Parameter Estimates (hr) (mg/L) ka = 2.365 hr-1 0.0 0.00 K = 0.06899 hr-1 0.25 0.88 T½ = 10.04 hr 0.5 1.40 AUCI =33.0 mg*hr/L 1 1.86 ka? 2.365 hr-1 ? 1.5 1.98 V/F = 175.69 when F=1 What would happened to ka if we 2 1.99 administered Moxi with food ? 4 1.77 8 1.34 or increased the dose? 12 24 1.02 0.44 Absorption Rate - ka ka is the absorption rate constant. It has units of hr-1. mg/L 10.00 Values of ka can <theoretically> range from 0 to , 1.00 but in reality the ka would never be less than 0.001 hr-1 or greater than 30 hr-1. 0.10 0 4 8 12 Hours 16 20 24 What is the difference between a value of 0.5 hr-1 vs. 2.3 hr-1? Absorption Rate - ka What is the difference between a value of 0.5 hr-1 vs. 2.3 hr-1? A larger ka value indicates faster absorption. Here both drugs have a 2 hour half-life (parallel terminal phase) Which profile is produced with a ka of 2.3 hr-1? Absorption Rate - ka What is the difference between a value of 0.5 hr-1 vs. 2.3 hr-1? Here both drugs have a 2 hour half-life. Which profile is produced with a ka of 2.3 hr-1? Dose 1 has a ka of 2.3 hr-1 and a Tmax of ~1 hr. Dose 2 has a ka of 0.5 hr-1 and a Tmax of ~2.4 hr. Absorption Rate - ka A ka value of 100 hr-1 is so fast that it resembles IV bolus injection. ka appears to determine Tmax…? ka= 100 Tmax = 0.05 hr ka= 2.3 Tmax = 0.98 hr ka= 0.5 Tmax = 2.39 hr … any other factors?? Dose 1 has a ka of 2.3 hr-1 and a Tmax of ~1 hr. Dose 2 has a ka of 0.5 hr-1 and a Tmax of ~2.4 hr. Dose 3 has a ka of 100 hr-1 and a Tmax of ~0.05 hr (3 minutes). Absorption Rate - ka K or Half-life also determines Tmax following the first dose. Formula: ln [ ka/k] TMAX = --------------ka - k Dose 1 has a ka of 1 hr-1 and a T-half 1 hr and T max of 1.2 hr. Dose 2 has a ka of 1 hr-1 and a T-half of 2hr and T max of 1.6 hr. Dose 3 has a ka of 1 hr-1 and a T-half of 10 hr and T max of 2.9 hr. Absorption Rate - ka Absorption from many formulations is usually first order … But does absorption occur at other rates???? Absorption Rate - ka Some modified release or sustained release formulations display zero-order absorption. A zero-order absorption rate concentration-time profile will appear different. The peak will be abrupt, not smooth and rounded. These profiles are shown with the same half-life (4 hr) but a different volume so that the profiles are separated. Absorption Rate - ka Zero-Order Rate 200 mg/hr Tmax = 2 hours A zero – order rate is Constant Each hour the same amount of drug (mg) is absorbed (or released) from the formulation. The entire dose of a 400 mg tablet that is absorbed at the zero-order rate of 200 mg/hr will all be absorbed in 2 hours. The peak will occur at 2 hours, regardless of the elimination rate Absorption Rate - ka Zero-Order Rate 200 mg/hr Tmax = 2 hours A first order rate is a constant percentage (not amount) per unit of time. A drug with ka = 0.693 hr-1, will peak at about 2.6 hours when the T½ = 4 hours. But when does absorption for this formulation stop? (i) At the Tmax – 2.6 hrs (ii) Prior to the peak (iii) ~ 1 hr after the peak (iv) Technically – never (v) It depends Absorption Rate - ka A first order rate Zero-Order Rate 200 mg/hr Tmax = 2 hours 6.25 mg/hr 25 mg/hr 100 mg/hr Such as 0.693 hr-1, will peak at about 2.6 hours when the T½ = 4 hours. If we deal with ka as we would K, since ka = 0.693, then T½ka = 1 hour. This means that following a 400 mg dose, rates/hr =: Time Amount 1 200 2 100 Peak 3 50 4 25 5 12.5 6 6.25 Absorption Rate - ka Zero-Order Rate 200 mg/hr Tmax = 2 hours A first order rate Such as 0.693 hr-1, will peak at about 2.6 hours when the T½ = 4 hours. But when does absorption for this formulation stop? (i) At the Tmax – 2.6 hrs (ii) Prior to the peak (iii) ~ 1 hr after the peak (iv) Technically – never (v) It depends Absorption Rate - ka K and ka are independent processes Factors which affect K Drug Patient Other drugs … Factors with affect ka Drug Patient Formulation Physiologic factors Food, GI environment Enzymes Absorption Rate - ka K and ka are independent processes Factors which affect K Drug Patient Other drugs … Factors with affect ka Drug Patient Formulation Physiologic factors Food, Water GI environment Enzymes Factors Affecting Bioavailability Physiologic factors 1. 2. 3. 4. 5. 6. pH Stomach ~ 1 and intestine ~ 6 Surface area of the of the intestine – microvilli Presence of carrier proteins for absorption & exsorption (Pgp) Enzymes; endogenous and bacterial GI blood flow Gastric Emptying & intestinal transit (Pgp or MDR1) Physicochemical Properties of the Drug 1. 2. 3. 4. 5. pKa Water & lipid solubility Molecular size Stability in GI environment (pH) Specificity for carrier proteins and enzymes (Pgp or MDR1) Factors Affecting Bioavailability Physiologic factors 1. 2. 3. 4. 5. 6. Factors which change pH Stomach ~ 1 and intestine ~ 6 Surface area of the of the intestine microvilli the –environment. Presence of carrier proteins for absorption & exsorption (Pgp) Enzymes; endogenous and bacterial FOOD GI blood flow Affects pH, Gastric Emptying & intestinal transit (Pgp MDR1) Bloodorflow Gastric emptying Interactions enzymes Physicochemical Properties of thewith Drug 1. 2. 3. 4. 5. pKa Water & lipid solubility DRUGS Molecular size Affect Blood flow Stability in GI environment (pH) Gastric emptying Specificity for carrier proteinsInteractions and enzymeswith (Pgpenzymes or MDR1) Absorption Rate - ka In the Excel® workbook ‘10 Bioavailability & Absorption Moxifloxacin’ in ‘Effect of ka or Dose’ sheet, you can enter in the vary the Dose, F, Half-life or ka in 3 different profiles (shaded green area) and a single dose profile out to 20 hours will be generated. Parameters are calculated below. Absorption Rate - ka What is a sustained release (SR, CD…) product? … what is different about these formulations compared to an immediate release formulations? What is their purpose or advantage? Absorption Rate - ka A sustained release (SR, CD…) product, generally has a much slower absorption rate (smaller ka value). Slowing the absorption rate is useful for drugs which are rapidly eliminated.(short T½) What does this do to the Cmax and Tmax of the product? Absorption Rate - ka T½ = 2 hours ka = 2.0 hr-1; 0.5 hr-1 & 0.1 hr-1 As ka is reduced and absorption slowed, Tmax increases & Cmax decreases. What happens to AUC? Absorption Rate - ka T½ = 2 hours ka = 2.0 hr-1; 0.5 hr-1 & 0.1 hr-1 As ka is reduced and absorption slowed, Tmax increases & Cmax decreases. AUC is not changed. (~28.9 mg*hr/L) What about T½ ? Absorption Rate - ka T½ = 2 hours ka = 2.0 hr-1; 0.5 hr-1 & 0.1 hr-1 As ka is reduced and absorption slowed, Tmax increases & Cmax decreases. AUC is not changed. (~28.9 mg*hr/L) What about T½ ? Should a formulation be able to affect the volume, clearance or half-life of a drug? Absorption Rate - ka T½ = 2 hours ka = 2.0 hr-1; 0.5 hr-1 & 0.1 hr-1 As ka is reduced and absorption slowed, Tmax increases & Cmax decreases. AUC is not changed. (~28.9 mg*hr/L) What about T½ ? Look at Dose 3 - T½ = 2 hr? Has reducing the ka to 0.1 hr-1 changed the half-life of the drug? Absorption Rate - ka Input: T½ = 2 hours ka = 2.0 hr-1; 0.5 hr-1 & 0.1 hr-1 but K from profile is 0.098 hr-1 for dose 3!..?? … the observed half-life has changed! Absorption Rate - ka T½ = 2 hr K= 0.34 hr-1 ka = 0.1 hr-1 T½ = 2 hr K= 0.34 hr-1 ka = 2 hr-1 A formulation change cannot modify the half-life, elimination rate or clearance of a drug, … only the appearance of the profile. A profile will always have the slowest (smallest) exponential in the terminal phase. Absorption Rate - ka T½ = 2 hr K= 0.34 hr-1 ka = 0.1 hr-1 A profile will always have the slowest (smallest) exponential in the terminal phase. Terminal phase rate constant: 0.1 hr-1 Rate constant from residual analysis: 0.34 hr-1. This is sometimes called the Flip-Flop model … but how does this occur… how does ka appear in the terminal phase? Absorption Rate - ka Rate limiting the Elimination Rate When absorption occurs quickly drug enters the body and ‘waits’ to be eliminated. Drug is observed to accumulate in the body and only when absorption is complete and the “tap” is turned off is the body finally able to clear drug and produce a declining concentration. The elimination rate is slower than the absorption rate. Absorption Rate - ka Rate limiting the Elimination Rate When absorption is very slow, drug can be eliminated from the body more quickly than it enters. This is like a bath tub. When the tap is on full, even when the plug is out, water begins to fill the tub. But when the tab is only dripping, water does not fill up the tub. In fact very little water would ever be in the tub (Cmax is lower) and the rate that water is leaving the tub is virtually equal to the rate that water enters the tub. Absorption Rate (ka) Summary K and ka determine Tmax in a single dose profile. As ka becomes smaller (slower), [at constant K] Tmax generally occurs later and the Cmax is lower. Changes in ka do not affect AUC, T½, Volume or Clearance. If ka is smaller than K, the rate constant observed in the terminal phase is ka. Absorption Rate (ka) Summary But what is an Enteric Coated formulation … Is ka affected? ka is the rate of absorption. At time zero the entire dose is in the stomach. The tablet or capsule must disintegrate and the drug dissolve before absorption can begin. Absorption Rate (ka) Summary But what is an Enteric Coated formulation Is ka affected? An Enteric Coated product delays initiation of absorption, generally by preventing disintegration. When does absorption begin? Gastric emptying time? ka may not be affected (all things being equal) The delay in the initiation of absorption is called a lag-time, … here about 3.75 hrs Absorption Rate (ka) Summary An Enteric Coated formulation delays the initiation of absorption by preventing disintegration and induces a lag time (TLAG) generally, to avoid gastric pH. A Sustained Release Formulation reduces the absorption rate (ka), generally to make a once daily or twice daily product. Both may be considered “Modified Release Formulations”